Alirocumab: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(Created page with "__NOTOC__ File:Pharmacologic-interventions-for-PCSK9.jpg|250px|thumb|right|Pharmacologic interventions for PCSK9 <font size="1">''Adapted from Journal of the American Colle...")
 
No edit summary
Line 2: Line 2:
[[File:Pharmacologic-interventions-for-PCSK9.jpg|250px|thumb|right|Pharmacologic interventions for PCSK9  <font size="1">''Adapted from Journal of the American College of Cardiology, 62(16): 1401-1408''<ref name="Urban-2013">{{Cite journal  | last1 = Urban | first1 = D. | last2 = Pöss | first2 = J. | last3 = Böhm | first3 = M. | last4 = Laufs | first4 = U. | title = Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. | journal = J Am Coll Cardiol | volume = 62 | issue = 16 | pages = 1401-8 | month = Oct | year = 2013 | doi = 10.1016/j.jacc.2013.07.056 | PMID = 23973703 }}</ref></font>]]
[[File:Pharmacologic-interventions-for-PCSK9.jpg|250px|thumb|right|Pharmacologic interventions for PCSK9  <font size="1">''Adapted from Journal of the American College of Cardiology, 62(16): 1401-1408''<ref name="Urban-2013">{{Cite journal  | last1 = Urban | first1 = D. | last2 = Pöss | first2 = J. | last3 = Böhm | first3 = M. | last4 = Laufs | first4 = U. | title = Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. | journal = J Am Coll Cardiol | volume = 62 | issue = 16 | pages = 1401-8 | month = Oct | year = 2013 | doi = 10.1016/j.jacc.2013.07.056 | PMID = 23973703 }}</ref></font>]]
'''For a review of all PCSK9 inhibitors please click [[PCSK9|here]]'''
'''For a review of all PCSK9 inhibitors please click [[PCSK9|here]]'''
{{SI}}
{{CMG}}
{{CMG}}
==Overview==
==Overview==

Revision as of 16:41, 10 November 2014

Pharmacologic interventions for PCSK9 Adapted from Journal of the American College of Cardiology, 62(16): 1401-1408[1]

For a review of all PCSK9 inhibitors please click here Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Properties

Major Trials

Phase II Trials

Phase III Trials

References

  1. ↑ Urban, D.; Pöss, J.; Böhm, M.; Laufs, U. (2013). "Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis". J Am Coll Cardiol. 62 (16): 1401–8. doi:10.1016/j.jacc.2013.07.056. PMID 23973703. Unknown parameter |month= ignored (help)


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Alirocumab&oldid=1040125"